Actively Recruiting
Evaluating Predominant Sensitization to Bee Venom Allergens as a Risk Factor for Immunotherapy Failure in Bee Venom Allergy
Led by Medical University of Graz · Updated on 2026-10-08
266
Participants Needed
3
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating why bee venom immunotherapy VIT is less effective than vespid VIT for patients with bee venom allergy. The study focuses on whether predominant sensitization to specific bee venom allergens, especially Api m 10, increases the risk of treatment failure. This multicenter observational study aims to clarify these risk factors to improve future bee venom treatments. Participants will receive bee venom immunotherapy following protocols chosen by the patients. Before treatment, blood samples will be collected to measure specific immunoglobulin E levels for different bee venom components. After reaching the maintenance dose, participants will undergo a sting challenge, and the outcomes will be recorded to assess treatment success or failure. Throughout the study, researchers will evaluate factors such as sensitization to various bee venom allergens, immunoglobulin G4 levels after treatment, systemic side effects, and use of antihypertensive medications. The main outcome is to determine if predominant Api m 10 sensitization is linked to treatment failure within about six months after the sting challenge. Participant involvement includes blood sampling and clinical assessments, with the total study period lasting until March 2029.
CONDITIONS
Brief Title
Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure
Research Team
G
Gunter J Sturm, MD, PhD
L
Lisa Arzt-Gradwohl, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here